Pharmacokinetic patterns of risperidone-associated adverse drug reactions

Schoretsanitis, Georgios; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Schruers, Koen R J; Walther, Sebastian; Lammertz, Sarah E; Haen, Ekkehard; Paulzen, Michael (2016). Pharmacokinetic patterns of risperidone-associated adverse drug reactions. European journal of clinical pharmacology, 72(9), pp. 1091-1098. Springer 10.1007/s00228-016-2085-2

[img] Text
art%3A10.1007%2Fs00228-016-2085-2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (340kB) | Request a copy

PURPOSE The aim of the study was to investigate a correlation between plasma concentrations of risperidone (RIS), its active metabolite 9-hydroxyrisperidone (9-OH-RIS) and the active moiety (AM) (RIS + 9-OH-RIS), and adverse drug reactions (ADRs) in a naturalistic sample. METHODS Plasma concentrations of RIS, 9-OH-RIS, and AM in patients out of a therapeutic drug monitoring (TDM) database complaining ADRs were categorized according to the Udvalg for Kliniske Undersogelser side effect rating scales (UKU) (n = 97) and compared to patients without ADRs (n = 398). RESULTS Patients in the ADR group received a significantly lower daily dosage of risperidone (trimmed mean 3.64 mg/day) than patients without ADRs (4.40 mg/day). No differences were found for active moiety plasma concentrations between the groups (p = 0.454). Differences were detected only in the case of dose-adjusted plasma concentration values (concentration-by-dose, C/D) for 9-OH-RIS, being higher in patients reporting ADRs (4.78 ng/mL/mg) than in patients without ADRs (4.3 ng/mL/mg) (p = 0.037 for Mann-Whitney U test). Note that differences for non-adjusted 9-OH-RIS plasma levels between groups failed to reach significance (p = 0.697). CONCLUSIONS Our findings are consistent with previous data supporting a prominent role of 9-hydroxyrisperidone, but not of risperidone with regard to ADRs. When studying the various subgroups of reported ADRs separately, the size of these subsamples offers some plausible limitations by reducing the power of the analysis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Translational Research Center
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Management
04 Faculty of Medicine > University Psychiatric Services

UniBE Contributor:

Schoretsanitis, Georgios and Walther, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0031-6970

Publisher:

Springer

Language:

English

Submitter:

Sebastian Walther

Date Deposited:

29 Aug 2016 09:46

Last Modified:

21 Sep 2016 15:48

Publisher DOI:

10.1007/s00228-016-2085-2

PubMed ID:

27376639

Uncontrolled Keywords:

Antipsychotics; Drug metabolism; Pharmacokinetics; Psychopharmacology; Schizophrenia

BORIS DOI:

10.7892/boris.86082

URI:

https://boris.unibe.ch/id/eprint/86082

Actions (login required)

Edit item Edit item
Provide Feedback